# 01 Inflammation, Immunology and Immunotherapeutics Program

> **NIH NIH P30** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2020 · $121,913

## Abstract

01 INFLAMMATION, IMMUNOLOGY AND IMMUNOTHERAPEUTICS (III) PROGRAM
ABSTRACT
Decades of research on basic immunology and the interactions of tumors and the immune system have led
over the past few years to an explosive increase in the successes of immunotherapeutic modalities in cancer.
The objective of the Inflammation, Immunology, and Immunotherapeutics (III) Program is to build on and to
accelerate those successes by developing novel therapeutic approaches for the treatment of
leukemia/lymphoma and solid tumors, and to understand and exploit the basic biology of the immune system's
responses to cancers. The emphasis is on antibody and T-cell mediated therapy in preclinical models and
clinical translation studies. The Tumor Immunology Program has been a component of the Cancer Center
since its inception and in 2012, it merged with the Virology Program to become the III Program. It is currently
led by Casey T. Weaver, M.D. (Pathology), and Donald J. Buchsbaum, Ph.D. (Radiation Oncology), and has
40 primary faculty members from seven departments. The Program has $11,611,410 in annual direct grant
support of cancer relevant research including $756,267 from NCI, $9,592,968 from other NIH Institutes,
$289,001 from other peer-reviewed awards, and $973,174 in non-peer-reviewed support. The Program has
two major areas of emphasis: (1) development of targeted immunotherapy utilizing antibody specificity to
deliver apoptotic stimuli, drugs, or radioactive isotopes to tumors in animal models and human cancer; and (2)
exploration of basic immunobiology research in the areas of inflammation and T- and B-cell immunology to
translate into immunodiagnostic and immunotherapeutic modalities. The Program has major collaborations
with the Experimental Therapeutics and Cancer Cell Biology Programs, and HudsonAlpha including individual
projects in the Breast Cancer and Pancreatic Cancer SPOREs. During the previous funding period there were
310 total publications, of which 72 (23%) were intra-programmatic, 69 (22%) inter-programmatic, and 161
(52%) inter-institutional.
1

## Key facts

- **NIH application ID:** 9895660
- **Project number:** 5P30CA013148-48
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Donald J Buchsbaum
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $121,913
- **Award type:** 5
- **Project period:** — → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9895660

## Citation

> US National Institutes of Health, RePORTER application 9895660, 01 Inflammation, Immunology and Immunotherapeutics Program (5P30CA013148-48). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9895660. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*